Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Valeant Pharmaceuticals Intl (VRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,159,814
  • Shares Outstanding, K 348,710
  • Annual Sales, $ 8,724 M
  • Annual Income, $ 2,404 M
  • 36-Month Beta -0.38
  • Price/Sales 0.97
  • Price/Cash Flow 1.87
  • Price/Book 1.80
  • Price/Earnings ttm 6.12
  • Earnings Per Share ttm 3.96
  • Most Recent Earnings 0.89 on 05/08/18
  • Next Earnings Date 08/14/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend 1.000 on 11/10/10
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/18
See More
  • Average Estimate 0.81
  • Number of Estimates 6
  • High Estimate 0.91
  • Low Estimate 0.71
  • Prior Year 1.05
  • Growth Rate Est. (year over year) -22.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.56 +3.72%
on 06/28/18
27.25 -14.13%
on 06/14/18
-3.46 (-12.88%)
since 06/13/18
3-Month
16.76 +39.62%
on 04/16/18
27.79 -15.80%
on 06/13/18
+6.25 (+36.44%)
since 04/13/18
52-Week
10.94 +113.89%
on 11/02/17
27.79 -15.80%
on 06/13/18
+6.11 (+35.34%)
since 07/13/17

Most Recent Stories

More News
International Ophthalmology and Optometry Devices Market Booming With New Growth Opportunities

MarketNewsUpdates.com News Commentary

VRX.TO : 30.80 (-3.33%)
EYC.VN : 0.185 (unch)
EYEG : 0.53 (-0.93%)
EYCCF : 0.1443 (-0.21%)
STAA : 41.05 (-0.48%)
AGN : 185.60 (+0.75%)
VRX : 23.40 (-3.43%)
Implied Volatility Surging for Valeant Pharmaceuticals (VRX) Stock Options

Investors in Valeant Pharmaceuticals (VRX) need to pay close attention to the stock based on moves in the options market lately.

VRX : 23.40 (-3.43%)
Drug Pricing in Focus Again as Trump Tweet Slams Pfizer

In a tweet, Trump says Pfizer and other U.S. drugmakers should be "ashamed" that they have raised drug prices for "no reason".

MYL : 38.15 (+0.79%)
MRK : 69.06 (+0.31%)
VRX : 23.40 (-3.43%)
PFE : 42.09 (+1.62%)
Bausch + Lomb Announces U.S. FDA Filing Acceptance For Loteprednol Etabonate Ophthalmic Gel, 0.38%

PDUFA Date Set for February 25, 2019

VRX.TO : 30.80 (-3.33%)
VRX : 23.40 (-3.43%)
Salix And US WorldMeds Enter Into Exclusive Co-Promotion Agreement For Opioid Withdrawal Treatment LUCEMYRA(TM) (lofexidine)

US WorldMeds, LLC and Salix Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention...

VRX.TO : 30.80 (-3.33%)
VRX : 23.40 (-3.43%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valeant Pharmaceuticals International, Inc. - VRX

NEW YORK, NY / ACCESSWIRE / June 23, 2018 / Pomerantz LLP is investigating claims on behalf of investors of Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company") (NYSE: VRX). Such investors...

VRX.TO : 30.80 (-3.33%)
VRX : 23.40 (-3.43%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valeant Pharmaceuticals International, Inc. - VRX

Pomerantz LLP is investigating claims on behalf of investors of Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company") . Such investors are advised to contact Robert S. Willoughby...

VRX.TO : 30.80 (-3.33%)
VRX : 23.40 (-3.43%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valeant Pharmaceuticals International, Inc. - VRX

Pomerantz LLP is investigating claims on behalf of investors of Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company") (NYSE: VRX). Such investors are advised to contact Robert S....

VRX.TO : 30.80 (-3.33%)
VRX : 23.40 (-3.43%)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Valeant Pharmaceuticals International, Inc. (VRX)

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company") (NYSE: VRX)....

VRX.TO : 30.80 (-3.33%)
VRX : 23.40 (-3.43%)
Valeant Down as FDA Refuses to Approve Duobrii For Psoriasis

Valeant (VRX) suffers a setback as the FDA issues a CRL for its plaque psoriasis lotion, Duobrii.

AGLE : 9.20 (-0.22%)
AZN : 38.12 (+0.42%)
ILMN : 325.88 (-0.34%)
VRX : 23.40 (-3.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade VRX with:

Business Summary

Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients....

See More

Key Turning Points

2nd Resistance Point 24.80
1st Resistance Point 24.10
Last Price 23.40
1st Support Level 23.03
2nd Support Level 22.66

See More

52-Week High 27.79
Last Price 23.40
Fibonacci 61.8% 21.35
Fibonacci 50% 19.36
Fibonacci 38.2% 17.38
52-Week Low 10.94

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar